Released Mar 5, 2026, before the open
10-K filed Mar 5, 2026, 64 days after period end · 0001171843-26-001337
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$15.72M-$15.72M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$17,990,000N/M
Operating Cash Flowderived-$13,254,000N/M
Free Cash Flowderived-$13,254,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$15.72M | -$15.03M | -$13.42M | -$11.59M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR